ansm
Agence nationale de sécurité du médicament
et des produits de santé

RÉPUBLIQUE FRANÇAISE

French National Agency for Medicines and Health Products Safety

CERTIFICATE NUMBER: ***17MB005HFR01***

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER [1, 2]

Part 1

Issued following an inspection in accordance with :
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of France confirms the following:
The manufacturer: ***LFB BIOMANUFACTURING***
Site address: ***avenue des Chênes Rouges, quartier du Rieu, ALES, 30100, France***

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC .

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on ***2017-02-03*** , it is considered that it complies with :

- The principles of GMP for active substances [3] referred to in Article 47 of Directive 2001/83/EC .

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

---

[1] *The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.*

[2] *Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.*

[3] *These requirements fulfil the GMP recommendations of WHO.*

143/147 boulevard Anatole France - F-93285 Saint-Denis Cedex - Tél.: +33 (0)1 55 87 30 00 - www.ansm.sante.fr

Part 2

Manufacture of active substance. Names of substances subject to inspection :
PROTEINS OBTAINED FROM MAMMALIAN CELLS CULTURE USED FOR CLINICAL TRIALS(en) / PROTEINES POUR ESSAIS CLINIQUES OBTENUES PAR CULTURE DE CELLULES DE MA MMIFERES(fr)
RECOMBINED HUMAN FACTOR VII ACTIVATED(en) / FACTEUR VII HUMAIN RECOMBINANT ACTIVE(fr)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance : PROTEINS OBTAINED FROM MAMMALIAN CELLS CULTURE USED FOR CLI NICAL TRIALS

3.3	**Manufacturing of Active Substance using Biological Processes**
	3.3.2 Cell Culture : Mammalian 3.3.3 Isolation / Purification
3.5	**General Finishing Steps**
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing

Active Substance : RECOMBINED HUMAN FACTOR VII ACTIVATED

3.3	**Manufacturing of Active Substance using Biological Processes**
	3.3.3 Isolation / Purification
3.5	**General Finishing Steps**
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing

143/147 boulevard Anatole France - F-93285 Saint-Denis Cedex - Tél.: +33 (0)1 55 87 30 00 - www.ansm.sante.fr

Clarifying remarks (for public users)

PROTEINS OBTAINED FROM MAMMALIAN CELLS CULTURE USED FOR CLINICAL TRIALS: According to chapter 19 of part II and annex 2 of the European good manufacturing practices ; RECOMBINED HUMAN FACTOR VII ACTIVATED: Limited to purification, according to part II and annex 2 of the European good manufacturing pratices.

2017-05-11

Name and signature of the authorised person of the Competent Authority of France

Le chef du pôle Inspection des produits biologiques 1
Romain ROTIVAL

Mr. Romain Rotival
French National Agency for Medicines and Health Products Safety
Tel: *+33155873967*
Fax: *+33155873972*

143/147 boulevard Anatole France - F-93285 Saint-Denis Cedex - Tél.: +33 (0)1 55 87 30 00 - www.ansm.sante.fr